ClinicalTrials.gg
CompletedNCT03684811Updated Nov 18, 2023Results posted

A Study of FT-2102 in Patients With Advanced Solid Tumors and Gliomas With an IDH1 Mutation

A Phase 1/2 interventional study of FT-2102 and Azacitidine in Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme), Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas) and Cohort 3a and 3b: Chondrosarcoma, sponsored by Forma Therapeutics, Inc.. Completed at 26 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-18.

Sponsored by Forma Therapeutics, Inc. (part of Novo Nordisk A/S) · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
93
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,302 studies in Glioblastoma with a site in United States — 194 open to participants now, 323 under way, 16 of them phase 3. Glioblastoma · United States.

Enrollment
173rd of 1,155
93 · median 33
Started
2018
with 71 others
Phase 1/2
190 of 1,302
32 open now
Registered
881st of 1,302
by date

Among the 1,302 studies in Glioblastoma with a site in United States, this one is the 173rd largest by enrollment of the 1,155 interventional ones that give a count, is one of 72 that started in 2018, is one of 190 in phase 1/2, and was the 881st registered.

Glioblastoma

2,135 studies on the registry are indexed under Glioblastoma; 465 are open to participants now.

Browse Glioblastoma studies →

Open to participants now

194 of the 1,302 studies in Glioblastoma with a site in United States are open now. Recruiting first, the newest first:

189 more — sign in →

All 194 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 338 Glioblastoma studies recruiting now, 233 (69%) set no upper age limit and 65 (19%) stop at 75 or younger; 27 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,302 studies in Glioblastoma with a site in United States, or all of them as a file.
02

Study summary

This Phase 1/2 study will evaluate the safety, efficacy, PK, and PD of FT-2102 as a single agent and in combination with other anti-cancer drugs in patients with advanced solid tumors and gliomas.

The study is divided into two parts: single agent FT-2102 followed by combination therapy.

Part 1: A single agent, open-label study in up to five cohorts (glioma, hepatobiliary tumors, chondrosarcoma, intrahepatic cholangiocarcinoma, and other IDH1 mutant solid tumors) that will include a Phase 1 dose confirmation followed by a Phase 2 investigation of clinical activity in up to 4 cohorts. During the dose confirmation, additional doses or altered dose schedules may be explored.

Part 2: An open-label study of FT-2102 in combination with other anti-cancer agents. Patients will be enrolled across 4 different disease cohorts, examining the effect of FT-2102 + azacitidine (glioma and chondrosarcoma), FT-2102 + nivolumab (hepatobiliary tumors), and FT-2102 + gemcitabine/cisplatin (intrahepatic cholangiocarcinoma). There will be a safety lead-in followed by a Phase 2 evaluation in up to four cohorts of patients.

03

Conditions studied

  • Cohort 1a and 1b: Glioma (Advanced Gliomas and Glioblastoma Multiforme)
  • Cohort 2a and 2b: Hepatobiliary Tumors (Hepatocellular Carcinoma, Bile Duct Carcinoma, Intrahepatic Cholangiocarcinoma, Other Hepatobiliary Carcinomas)
  • Cohort 3a and 3b: Chondrosarcoma
  • Cohort 4a and 4b: Intrahepatic Cholangiocarcinoma
  • Cohort 5a: Other Non-Central Nervous System Solid Tumors With IDH1 Mutations

Keywords

  • Olutasidenib
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients must have documented IDH1-R132 gene-mutated disease as evaluated by site
  • Glioma: Advanced glioma that has recurred or progressed following standard therapy, or that has not responded to standard therapy.
  • Hepatobiliary cancer that is or intolerant to approved standard-of-care therapy (including: hepatocellular carcinoma, bile duct carcinoma, intrahepatic cholangiocarcinoma or other hepatobiliary carcinomas)
  • Chondrosarcoma that is relapsed or refractory and either locally advanced or and not amenable to complete surgical excision
  • Intrahepatic cholangiocarcinoma that is advanced nonresectable or metastatic cholangiocarcinoma not eligible for curative resection or transplantation. Phase 1b/Safety Lead-in of Phase 2: relapsed or refractory disease. Combination Phase 2 (beyond Safety Lead-in): have received no more than 1 cycle of gemcitabine/cisplatin therapy
  • Other solid tumors that have relapsed or refractory to standard-of-care therapy with no other available therapeutic options
  • Good performance status
  • Good kidney and liver function

Key Exclusion Criteria:

  • Prior solid organ or hematopoietic cell transplant
  • Prior treatment with IDH1 inhibitor (single agent cohorts only)
  • Congestive heart failure ( Class III or IV) or unstable angina pectoris. Previous history of myocardial infarction within 1 year prior to study entry, uncontrolled hypertension or uncontrolled arrhythmias
  • Unstable or severe, uncontrolled medical condition (e.g., unstable cardiac function, unstable pulmonary condition, including pneumonitis and/or interstitial lung disease, and uncontrolled diabetes)
  • Active, uncontrolled bacterial, viral, or fungal infections, requiring systemic therapy
  • only: active disease
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
93 participants (actual)

Study arms

  • Experimental
    Phase 1b Dose Confirmation Single Agent (Cohorts 1a-5a)

    Drug: FT-2102

  • Experimental
    Phase 2 Cohorts FT-2102 Single Agent (Cohorts 1a-5a)

    Drug: FT-2102

  • Experimental
    Phase 1b and 2 Cohorts Combination (Cohorts 1b and 3b)

    Drug: FT-2102 · Drug: Azacitidine

  • Experimental
    Phase 1b and 2 Cohort Combination (Cohort 2b)

    Drug: FT-2102 · Biological: Nivolumab

  • Experimental
    Phase 1b and 2 Cohort Combination (Cohort 4b)

    Drug: FT-2102 · Drug: Gemcitabine and Cisplatin

Interventions

  • FT-2102 will be supplied as a 150 mg capsule and will be administered per the protocol defined frequency and dose level.

  • Azacitidine will be administered per the site's standard of care.

    Also known as: Vidaza

  • BiologicalNivolumab

    Nivolumab will be administered per the site's standard of care.

    Also known as: Opdivo

  • DrugGemcitabine and Cisplatin

    Drug pages: Gemcitabine · Cisplatin

    Gemcitabine and cisplatin will be administered per the site's standard of care.

    Also known as: Gemzar and Platinol

06

What researchers measure

Primary outcomes

  1. Number of Participants With a Dose Limiting Toxicity (DLT)

    DLTs are AEs unrelated to the underlying disease and considered related to FT-2102. For non-hematologic AEs: Grade 3 or higher per CTCAE v 4.03 criteria except Grade 3 nausea, vomiting, diarrhea, or rash: lasting \<72 hours (with optimal medical management) or clinically relevant Grade 3 or higher non-hematologic laboratory finding. For hematologic AEs: Grade 3 or higher thrombocytopenia or febrile neutropenia or Grade 4 or higher neutropenia lasting for \>7 days.

    Time frame: Day 1-28

  2. Overall Response Rate (ORR)

    ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) as per RANO (2010) criteria for patients with high grade glioma (Cohorts 1a and 1b). For patients with low grade glioma, ORR is defined as CR+PR+minor response (MR) as per LGG RANO criteria (2011). For Cohorts 2-5, ORR is defined as CR+PR as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.

    Time frame: While on treatment

Secondary outcomes

  1. Area Under the Plasma Concentration Versus Time Curve (AUC)

    Area under the plasma concentration versus time curve (AUC) summarized for Cycle 1 and Cycle 2

    Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).

  2. Peak Plasma Concentration (Cmax)

    Peak Plasma Concentration (Cmax) was summarized for Cycle 1 and Cycle 2.

    Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).

  3. Time of Peak Plasma Concentration (Tmax)

    Time of peak plasma concentration (Tmax) was summarized for Cycle 1 and Cycle 2.

    Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).

  4. Time for Half of the Drug to be Absent in Blood Stream Following Dose (T 1/2)

    Time for half of the drug to be absent in blood stream following dose (T 1/2)

    Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).

  5. Apparent Clearance (CL/F)

    Rate at which drug is removed from the blood stream (CL/F).

    Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).

  6. Rate of Drug Distribution Within the Blood Stream (Vd/F)

    Rate of drug distribution within the blood stream (Vd/F)

    Time frame: Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).

  7. Olutasidenib Concentration Within Cerebro-spinal Fluid (CSF)

    Olutasidenib concentration within CSF (Glioma Cohorts 1-A and 1-B only). Due to sparse data, analysis was not conducted by timepoint.

    Time frame: CSF sample for drug concentration was collected at Day 1 of Cycles 1 and 3 (each cycle is 28 days) and through study completion, up to 24 weeks, on average.

  8. Progression-Free Survival (PFS)

    Progression-Free Survival from time of entry on study. Progression-free survival (PFS) is defined as the time from the first dose to disease progression as determined by applicable disease criteria or death due to any cause, whichever was sooner. Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit

    Time frame: From time of entry on study through progression, up to 24 weeks, on average

  9. Time to Progression (TTP)

    Time to progression is defined as the time (in weeks) from start of treatment until disease specified progression.

    Time frame: From first dose of study drug through time of disease progression

  10. Duration of Response (DOR)

    Duration of response (DOR), defined as the time from the first response to documented disease progression as determined by applicable disease criteria. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5). Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit

    Time frame: From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 44 weeks

  11. Overall Survival (OS)

    Overall survival (OS), defined as the time in weeks from the first dose to death due to any cause or date last known alive at end of follow-up

    Time frame: From date of first dose until the date of death from any cause, assessed up to 101 weeks

  12. Time to Response (TTR)

    Time to response (TTR) in weeks. TTR is defined as the time from first dose to first response. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5).

    Time frame: Response may be observed from time of first dose through time of treatment discontinuation, up to 2 years.

07

Results

Posted Jan 25, 2023

Participant flow

Participant flow — Overall Study
MilestoneCohort 1ACohort 1BCohort 2ACohort 2BCohort 3ACohort 3BCohort 4ACohort 4BCohort 5A
Started266802302406
Completed000000000
Not completed266802302406

Outcome measures

PrimaryNumber of Participants With a Dose Limiting Toxicity (DLT)

DLTs are AEs unrelated to the underlying disease and considered related to FT-2102. For non-hematologic AEs: Grade 3 or higher per CTCAE v 4.03 criteria except Grade 3 nausea, vomiting, diarrhea, or rash: lasting \<72 hours (with optimal medical management) or clinically relevant Grade 3 or higher non-hematologic laboratory finding. For hematologic AEs: Grade 3 or higher thrombocytopenia or febrile neutropenia or Grade 4 or higher neutropenia lasting for \>7 days.

Time frame:
Day 1-28
Reported as:
Count of participants · Participants
Number of Participants With a Dose Limiting Toxicity (DLT)
ParticipantsCohort 1ACohort 1BCohort 3ACohort 5A
Number of Participants With a Dose Limiting Toxicity (DLT)0201
PrimaryOverall Response Rate (ORR)

ORR is defined as the proportion of patients who achieved a complete response (CR) or partial response (PR) as per RANO (2010) criteria for patients with high grade glioma (Cohorts 1a and 1b). For patients with low grade glioma, ORR is defined as CR+PR+minor response (MR) as per LGG RANO criteria (2011). For Cohorts 2-5, ORR is defined as CR+PR as per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 criteria.

Time frame:
While on treatment
Reported as:
Count of participants · Participants
Overall Response Rate (ORR)
ParticipantsCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Overall Response Rate (ORR)201000
SecondaryArea Under the Plasma Concentration Versus Time Curve (AUC)

Area under the plasma concentration versus time curve (AUC) summarized for Cycle 1 and Cycle 2

Time frame:
Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Reported as:
Mean · h*ng/mL
Area Under the Plasma Concentration Versus Time Curve (AUC)
h*ng/mLCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Cycle 16840 ± 3062.96190 ± 2113.013140 ± 6018.912000 ± 2907.110780 ± 6379.111030 ± 6781.6
Cycle 220390 ± 5975.521210 ± 5775.027580 ± 4531.328170 ± 9052.524400 ± 8663.139540 ± 12573
SecondaryPeak Plasma Concentration (Cmax)

Peak Plasma Concentration (Cmax) was summarized for Cycle 1 and Cycle 2.

Time frame:
Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Reported as:
Mean · ng / mL
Peak Plasma Concentration (Cmax)
ng / mLCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Cycle 1388.1 ± 154.92369.5 ± 127.84879.4 ± 432.37863.4 ± 313.71744.1 ± 526.73815.4 ± 432.32
Cycle 22965 ± 917.892870 ± 540.284045 ± 527.024104 ± 1326.03650 ± 985.065663 ± 1897.8
SecondaryTime of Peak Plasma Concentration (Tmax)

Time of peak plasma concentration (Tmax) was summarized for Cycle 1 and Cycle 2.

Time frame:
Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Reported as:
Median · hours
Time of Peak Plasma Concentration (Tmax)
hoursCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Cycle 14.18 (1.95 to 20.25)3.95 (1.92 to 27.23)15.27 (2.03 to 24.33)16.37 (1.02 to 23.92)7.50 (1.00 to 24.00)4.17 (1.00 to 23.05)
Cycle 21.97 (0.00 to 7.57)4.00 (3.97 to 4.05)1.05 (1.00 to 7.85)1.98 (0.95 to 4.00)1.04 (0.00 to 4.22)1.52 (0.00 to 7.58)
SecondaryTime for Half of the Drug to be Absent in Blood Stream Following Dose (T 1/2)

Time for half of the drug to be absent in blood stream following dose (T 1/2)

Time frame:
Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Reported as:
Mean · ng / mL
Time for Half of the Drug to be Absent in Blood Stream Following Dose (T 1/2)
ng / mLCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Time for Half of the Drug to be Absent in Blood Stream Following Dose (T 1/2)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
SecondaryApparent Clearance (CL/F)

Rate at which drug is removed from the blood stream (CL/F).

Time frame:
Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Reported as:
Geometric mean · units
Apparent Clearance (CL/F)
unitsCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Apparent Clearance (CL/F)NA ± NANA ± NANA ± NANA ± NANA ± NANA ± NA
SecondaryRate of Drug Distribution Within the Blood Stream (Vd/F)

Rate of drug distribution within the blood stream (Vd/F)

Time frame:
Cycles 1: Day 1 (0, 1, 2, 4, 8 hours post dose), Days 2, 8, 15, 22 pre dose. Cycles 2 Day 1 (0, 1, 2, 4, 8 hours post dose).
Reported as:
Number · units
Rate of Drug Distribution Within the Blood Stream (Vd/F)
unitsCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Rate of Drug Distribution Within the Blood Stream (Vd/F)NANANANANANA
SecondaryOlutasidenib Concentration Within Cerebro-spinal Fluid (CSF)

Olutasidenib concentration within CSF (Glioma Cohorts 1-A and 1-B only). Due to sparse data, analysis was not conducted by timepoint.

Time frame:
CSF sample for drug concentration was collected at Day 1 of Cycles 1 and 3 (each cycle is 28 days) and through study completion, up to 24 weeks, on average.
Reported as:
Mean · ng/mL
Olutasidenib Concentration Within Cerebro-spinal Fluid (CSF)
ng/mLCohort 1ACohort 1B
Olutasidenib Concentration Within Cerebro-spinal Fluid (CSF)27.15 ± 6.57—
SecondaryProgression-Free Survival (PFS)

Progression-Free Survival from time of entry on study. Progression-free survival (PFS) is defined as the time from the first dose to disease progression as determined by applicable disease criteria or death due to any cause, whichever was sooner. Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit

Time frame:
From time of entry on study through progression, up to 24 weeks, on average
Reported as:
Median · weeks
Progression-Free Survival (PFS)
weeksCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Progression-Free Survival (PFS)8.21 (7.14 to 37.50)8.29 (8.14 to 9.43)NA (7.00 to NA)8.57 (7.43 to 22.14)8.29 (7.00 to 17.71)8.07 (7.57 to 31.00)
SecondaryTime to Progression (TTP)

Time to progression is defined as the time (in weeks) from start of treatment until disease specified progression.

Time frame:
From first dose of study drug through time of disease progression
Reported as:
Median · weeks
Time to Progression (TTP)
weeksCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Time to Progression (TTP)8.21 (7.14 to 37.50)8.29 (8.14 to 9.43)NA (7.0 to NA)15.00 (7.43 to 24.00)13.86 (7.29 to 24.14)8.14 (8.00 to 31.00)
SecondaryDuration of Response (DOR)

Duration of response (DOR), defined as the time from the first response to documented disease progression as determined by applicable disease criteria. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5). Disease progression as measured by the appropriate response criteria, unless deemed by the Investigator to be receiving clinical benefit

Time frame:
From date of first dose until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 44 weeks
Reported as:
Median · weeks
Duration of Response (DOR)
weeksCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Duration of Response (DOR)43.71 (43.71 to 43.71)—NA (NA to NA)———
SecondaryOverall Survival (OS)

Overall survival (OS), defined as the time in weeks from the first dose to death due to any cause or date last known alive at end of follow-up

Time frame:
From date of first dose until the date of death from any cause, assessed up to 101 weeks
Reported as:
Median · weeks
Overall Survival (OS)
weeksCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Overall Survival (OS)75.00 (45.86 to NA)NA (NA to NA)NA (32.00 to NA)NA (23.14 to NA)36.43 (10.29 to NA)NA (33.71 to NA)
SecondaryTime to Response (TTR)

Time to response (TTR) in weeks. TTR is defined as the time from first dose to first response. First response is defined as first observation of overall response of CR+PR+MR (glioma) or CR+PR (Cohort 2-5).

Time frame:
Response may be observed from time of first dose through time of treatment discontinuation, up to 2 years.
Reported as:
Median · weeks
Time to Response (TTR)
weeksCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Time to Response (TTR)38.07 (8.29 to 67.86)—31.43 (31.43 to 31.43)———

Adverse events

Collected over From first dose of study drug up to 28 days after last dose (Up to approximately 2 years). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1A2/26 (7.7%)11/26 (42.3%)26/26 (100%)
Cohort 1B0/6 (0%)3/6 (50%)6/6 (100%)
Cohort 2A0/8 (0%)5/8 (62.5%)8/8 (100%)
Cohort 3A2/23 (8.7%)12/23 (52.2%)21/23 (91.3%)
Cohort 4A4/24 (16.7%)9/24 (37.5%)23/24 (95.8%)
Cohort 5A1/6 (16.7%)1/6 (16.7%)6/6 (100%)
Most frequent serious events
Showing 10 of 34
Most frequent serious events
EventCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Disease ProgressionGeneral disorders6/261/61/85/236/241/6
HyperbilirubinaemiaHepatobiliary disorders0/261/60/80/230/240/6
Hepatic enzyme increasedInvestigations0/261/60/81/230/240/6
Decreased appetiteMetabolism and nutrition disorders0/260/60/80/230/241/6
Abdominal infectionInfections and infestations0/260/61/80/230/240/6
Spinal compression fractureInjury, poisoning and procedural complications0/260/61/80/230/240/6
HypercalcaemiaMetabolism and nutrition disorders0/260/61/80/231/240/6
HeadacheNervous system disorders0/260/61/80/230/240/6
SeizureNervous system disorders2/260/60/81/230/240/6
Anal incontinenceGastrointestinal disorders0/260/60/81/230/240/6
Most frequent other events
Showing 10 of 115
Most frequent other events
EventCohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5A
Alanine aminotransferase increasedInvestigations8/265/63/87/239/244/6
NauseaGastrointestinal disorders14/264/66/815/239/244/6
Aspartate aminotransferase increasedInvestigations5/264/62/87/2311/244/6
Blood alkaline phosphatase increasedInvestigations2/262/64/86/238/244/6
ConstipationGastrointestinal disorders7/262/64/87/236/243/6
DiarrhoeaGastrointestinal disorders8/261/61/82/235/243/6
VomitingGastrointestinal disorders5/261/62/83/233/243/6
FatigueGeneral disorders13/262/63/87/238/241/6
Neutrophil count decreasedInvestigations1/263/61/81/232/240/6
Decreased appetiteMetabolism and nutrition disorders3/260/64/810/235/243/6

Baseline characteristics

Safety Analysis Set - Patients who have received at least one dose of study medication.

Age, Continuous
Age, Continuous(years)Cohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5ATotal
Mean44.8 ± 9.1342.0 ± 7.2159.9 ± 10.4755.1 ± 10.6857.1 ± 12.5661.3 ± 18.352.7 ± 12.6
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5ATotal
Female926617444
Male1742177249
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5ATotal
Hispanic or Latino2102207
Not Hispanic or Latino22551516467
Unknown or Not Reported20366219
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cohort 1ACohort 1BCohort 2ACohort 3ACohort 4ACohort 5ATotal
American Indian or Alaska Native0000000
Asian0030115
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000101
White25631717371
More than one race0000000
Unknown or Not Reported10265216
08

Study locations

26 sites
  • Banner MD Anderson
    Gilbert, Arizona 85234, United States
  • University of Colorado Anschutz Medical Campus
    Aurora, Colorado 80045, United States
  • University of Miami, Sylvester Comprehensive Cancer Center
    Miami, Florida 33136, United States
  • Northwestern University, Lurie Comprehensive Cancer Center
    Chicago, Illinois 60611, United States
  • University of Iowa, Holden Comprehensive Cancer Institute
    Iowa City, Iowa 52242, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Henry Ford Hospital
    Detroit, Michigan 48202, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Rutgers Cancer Institute of New Jersey
    New Brunswick, New Jersey 08901, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Baylor Scott and White Medical Center
    Temple, Texas 76508, United States
  • University of Utah, Huntsman Cancer Hospital
    Salt Lake City, Utah 84112, United States
  • Medical College of Wisconsin, Froedtert Hospital
    Milwaukee, Wisconsin 53226, United States
  • Austin Hospital
    Heidelberg, Victoria 3084, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, VIC 3000, Australia
  • Centre de Lutte Contre Cancer (CLCC) - Institute Bergonie
    Bordeaux, 33076, France
  • Centre de Lutte Cancre (CLCC) - Lyon
    Lyon, France
  • Hospital de la Timone
    Marseille, 13385, France
  • Institut Gustave Roussy Cancer Campus
    Villejuif, 94800, France
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Asan Medical Center
    Seoul, 05505, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Vall D'Hebron University Hospital
    Barcelona, 08035, Spain
  • Cancer Research Beatson Institute
    Glasgow, G12 OYN, United Kingdom
  • The Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2018 to primary completion in May 2021, 30 months.

Results were first posted in Jan 2023, 1 year 8 months after primary completion. A results delay was requested in May 2022.

Of 53 industry-sponsored phase 1/2 interventional studies under Glioblastoma, half reached primary completion within 55 months of starting (the median), counting those still running; a quarter within 39 and three quarters within 75. This study's 30 months is below that.

Counting every sponsor, half of 138 studies reached it within 68 months; a quarter within 47 and three quarters within 102.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 17, 2018
First posted
Sep 26, 2018
StartActual
Nov 1, 2018
Primary completionActual
May 24, 2021
CompletionActual
Jun 13, 2022
Results delay requested
May 24, 2022
Results first posted
Jan 25, 2023
Last update
Nov 18, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03684811
Responsible party
Sponsor
First posted
Sep 26, 2018
Start date
Nov 1, 2018
Primary completion
May 24, 2021
Completion
Jun 13, 2022
Results posted
Jan 25, 2023
Last update
Nov 18, 2023

Study contacts

Emma Barrett
study director · Forma Therapeutics

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Olutasidenib

Start the discussion